Mood disorder in idiopathic pulmonary fibrosis: response to pulmonary rehabilitation
暂无分享,去创建一个
C. Nolan | W. Man | J. Walsh | R. Barker | O. Polgar | J. Harvey | S. Patel | George D Edwards | George Edwards
[1] R. Casaburi,et al. The effectiveness of pulmonary rehabilitation on chronic obstructive pulmonary disease patients with concurrent presence of comorbid depression and anxiety. , 2022, Respiratory medicine.
[2] S. Schofield,et al. Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD , 2021, Chest.
[3] Y. Erdoğan,et al. EVALUATION OF ANXIETY AND DEPRESSION IN IDIOPATHIC PULMONARY FIBROSIS , 2020, Middle Black Sea Journal of Health Science.
[4] S. Kon,et al. Anxiety and depression in bronchiectasis: Response to pulmonary rehabilitation and minimal clinically important difference of the Hospital Anxiety and Depression Scale , 2020, Chronic respiratory disease.
[5] A. Prasse,et al. Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial , 2020, Journal of clinical medicine.
[6] N. Koulouris,et al. Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis , 2020, Frontiers in Medicine.
[7] K. Janssen,et al. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study , 2020, Respiratory research.
[8] J. Reed,et al. Establishing the Minimal Clinically Important Difference for the Hospital Anxiety and Depression Scale in Patients With Cardiovascular Disease , 2019, Journal of cardiopulmonary rehabilitation and prevention.
[9] F. Demirci,et al. Are Idiopathic Pulmonary Fibrosis Patients more Anxious and Depressive than Patient’s with Other Interstitial Lung Disease? , 2019, Turkish Thoracic Journal.
[10] S. Birring,et al. King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference , 2019, European Respiratory Journal.
[11] S. Han,et al. Longitudinal Comparison of Anxiety and Depression Between Idiopathic Pulmonary Fibrosis (IPF) and Non-IPF Interstitial Lung Disease: A Prospective Cohort Study , 2019, B46. IDIOPATHIC INTERSTITIAL PNEUMONIA: NATURAL HISTORY.
[12] N. T. Andersen,et al. A web-based platform to accommodate symptoms of anxiety and depression by featuring social interaction and animated information in patients undergoing lumbar spine fusion: a randomized clinical trial. , 2019, The spine journal : official journal of the North American Spine Society.
[13] E. Yalnız,et al. Does the severity of interstitial lung disease affect the gains from pulmonary rehabilitation? , 2018, The clinical respiratory journal.
[14] Jong Sun Park,et al. Clinical impact of depression and anxiety in patients with idiopathic pulmonary fibrosis , 2017, PloS one.
[15] P. Cullinan,et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study , 2017, Thorax.
[16] C. Ryerson,et al. Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.
[17] W. Cooper,et al. Health‐related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry , 2017, Respirology.
[18] M. Ando,et al. Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis , 2017, Internal medicine.
[19] A. Holland,et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial , 2017, Thorax.
[20] D. Needham,et al. Distribution-based estimates of minimal important difference for hospital anxiety and depression scale and impact of event scale-revised in survivors of acute respiratory failure. , 2016, General hospital psychiatry.
[21] N. Kaminski,et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. , 2015, Chest.
[22] J. Fiore,et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease , 2014, Respirology.
[23] R. Abouqal,et al. Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab , 2014, Clinical Rheumatology.
[24] S. Kon,et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.
[25] S. Kon,et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference , 2013, Thorax.
[26] Robin P. Smith,et al. Depression in patients with idiopathic pulmonary fibrosis , 2013, Chronic respiratory disease.
[27] C. Fell. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. , 2012, Clinics in chest medicine.
[28] S. D'Amore,et al. [Hospital anxiety and depression]. , 2011, Reumatismo.
[29] B. Make,et al. Benefits of Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis , 2011, Respiratory Care.
[30] N. Kaminski,et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. , 2010, Heart & lung : the journal of critical care.
[31] H. Collard,et al. Pulmonary rehabilitation for interstitial lung disease. , 2010, Chest.
[32] H. Schünemann,et al. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease , 2008, Health and quality of life outcomes.
[33] R. Hays,et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. , 2008, Journal of clinical epidemiology.
[34] Sally J. Singh,et al. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR) , 2001, Thorax.
[35] P. Jones,et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.
[36] G. Guyatt,et al. Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.
[37] Huston Gj,et al. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.
[38] E. Wouters,et al. Responsiveness and MCID Estimates for CAT, CCQ, and HADS in Patients With COPD Undergoing Pulmonary Rehabilitation: A Prospective Analysis. , 2017, Journal of the American Medical Directors Association.
[39] S. Nathan,et al. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. , 2017, The Lancet. Respiratory medicine.